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Objective: Resveratrol (RSV) is the most studied natural compound that activates sirtuins, which
produce beneﬁcial metabolic effects on lipid and glucose metabolism. The aim of the present study
was to investigate the role of resveratrol in preventing nonalcoholic fatty liver disease (NAFLD) and
expression of liver inﬂammatory markers in mice treated with a high-fat diet.
Methods and procedures: Eighteen male mice were divided into three groups and fed for 60 d with
a standard diet (ST), high-fat diet (HFD), or high-fat diet plus resveratrol (HFD þ RSV, 30 mg/kg/d).
Body weight, food intake, and serum total cholesterol, triacylglycerol, insulin, alanine transaminase
(ALT), and aspartate aminotransferase (AST) were evaluated. Liver histology was analyzed.
Expression of ACC, PPAR-g, ChREBP, SREBP-1 c, CPT-1, tumor necrosis factor a (TNF-a), interleukin
6 (IL-6), NF-kB, interleukin 1 b (IL-1 b), and SIRT1 were evaluated by quantitative real-time reverse
transcriptase PCR (qRT-PCR).
Results: The major ﬁnding of the present study was that RSV reduced body fat, total cholesterol,
triacylglycerol, transaminases, and insulin plasma level. These results were accompanied with a
signiﬁcant reduction in TNF-a, IL-6, and NF-kB mRNA expression in the liver. Analyses of liver
adipogenesis related genes indicated that ACC, PPAR-g, and SREBP-1 mRNA expression were
signiﬁcantly suppressed in HFD þ RSV mice. In addition, we observed increased expression of
SIRT1 in the HFD þ RSV group.
Conclusions: We observed that treatment with resveratrol improved lipid metabolism, and
decreased NAFLD and pro-inﬂammatory proﬁle in liver of mice with obesity-inducible diets. These
data suggest an important clinical application of RSV in preventing liver diseases.
 2014 Elsevier Inc. All rights reserved.Introduction
Obesity is a metabolic state associated with several hepatic
abnormalities and increased risk of chronic diseases such as type
2 diabetes, cardiovascular diseases, and cancer [1]. Obesity
is described as a major risk factor for nonalcoholic fatty liverx: (55-31) 3409 2695.
S. Santos).
ll rights reserved.disease (NAFLD), a disease spectrum that includes hepatic stea-
tosis, steatohepatitis, ﬁbrosis, and liver cirrhosis [2–4].
Nonalcoholic fatty liver disease is one of the most common
manifestations of chronic liver disorders worldwide [4]. NAFLD
represents a continuum of hepatic injuries, which progress from
simple hepatic steatosis to nonalcoholic steatohepatitis, with
some people even ultimately progressing to ﬁbrosis, cirrhosis,
and liver failure [5]. The prevalence of NAFLD in the general
population is estimated to be between 14% and 24%, and it
is so closely associated with obesity, diabetes, and insulin
Fig. 1. Plasma parameters, liver histology and analyses of mRNA expression of adipogenesis to related genes by qRT to PCR in liver. (A) Total cholesterol. (B) Triacylglycerols.
(C) HDL. (D) ALT. (E) AST. (F) HE staining of liver sample mice. Inlet: HE staining. Scale bar: 20. *P < 0.05, yP < 0.01 among HFD versus ST and HFD þ RSV.
J. M. O. Andrade et al. / Nutrition 30 (2014) 915–919916resistance (IR) that it has been proposed that NAFLD be included
as a component of metabolic disorders [6,7].
Resveratrol (3,5,40-trihydroxystilbene) is a natural poly-
phenolic compound found in grapes and red wine that has been
shown to extend lifespan in many organisms [8,9]. In the last few
years, interest in resveratrol has substantially increased, and its
broad biological activity at the cellular level has been demon-
strated. The cardioprotective [10–12], anticancer [13], antiin-
ﬂammatory, and antioxidant [14] properties of resveratrol are
quitewell characterized. In recent animal studies, resveratrol has
produced promising protective effects on the liver against lipid
accumulation induced by a high-fat diet [8,9,15].
Resveratrol is a natural compound that activates sirtuins
(SIRT), the mammalian homolog of yeast silent information
regulator 2 (Sir2). SIRT is a highly conserved family of proteins,
with one or more sirtuins present in virtually all species from
bacteria to mammals [16,17]. Recent studies have indicated that
SIRTexpression in the liver is signiﬁcantly decreased in an NAFLD
model of rats fed a high-fat diet, and moderate SIRT1 over-
expression protects mice from developing NAFLD [18,19].
Thus in this study we aimed to investigate whether RSV
treatment could improve NAFLD, and we explored the possible
mechanisms associated with lipogenesis and inﬂammation.
A deeper understanding of the role of RSV in modulating thebiological markers of NAFLD will substantiate its potential as a
therapeutic candidate.
Materials and methods
Animals
The experiment was conducted with 18 male FVB/N mice (4 wk old), which
were randomly divided into three groups (n¼ 6) and fed the following respective
experimental diets for 60 d: Standard diet (ST); high-fat diet (HFD); high-fat diet
plus resveratrol (HFD þ RSV) (30 mg/kg/d) [8,20,21]. According to previous
studies, the FVB/N strain is considered a preferable model for evaluation of
metabolic disorders [22,23].
Diets
The standard diet (Labina, Purina, St. Louis, MO, USA) used for regular
maintenance of the mice is composed of 50.30% carbohydrate, 41.90% protein,
and 7.80% fat, with a total of 2.18 kcal per 1 g of diet. The high-fat diet was
composed 24.55% of carbohydrate, 14.47% of protein, and 60.98% of fat, pre-
senting a total of 5.28 kcal per 1 g of diet. All the high-fat diet components were
purchased from Rhoster LTDA (S~ao Paulo, Brazil).
Measurements of body weight, food intake, and tissue collection
The mice were individually housed and the food intake was measured twice
perweekduring treatment to determine food efﬁciency (food intake/bodyweight).
Overnight-fasted mice were sacriﬁced with ketamine (130 mg/kg) and xylazine
Fig. 2. Analyses of mRNA expression of lipogenesis markers by qRT to PCR in liver. (A) ACC. (B) PPARg. (C) SREBP-1 c. (D) ChREBP. (E) CPT-1. Control mice (ST; white bars),
high-fat diet (HFD; black bars), and high-fat diet plus resveratrol (HFD þ RSV; gray bars). *P < 0.05, yP < 0.01 among HFD versus ST and HFD þ RSV.
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diately frozen in liquid nitrogen and stored at80C for posterior analysis.
Determination of blood measurements
Serum was obtained after centrifugation (3200 rpm for 10 min at 4C). Total
serum cholesterol, high-density lipoprotein (HDL), triacylglycerol, insulin, and
aspartate and alanine transaminases (AST and ALT) were assayed using enzy-
matic kits (Wiener Laboratories, Rosario, Argentina).
Reverse transcription and qRT-PCR
Total RNA from liver tissue was prepared using TRIzol reagent (Invitrogen
Corp., San Diego, CA, USA), treated with DNAse and reverse transcribed with M-
MLV (Invitrogen Corp.) using random hexamer primers. The endogenous glyc-
eraldehydes-3-phosphate dehydrogenase (GAPDH) (internal control), interleukin
1 b (IL-1 b), tumor necrosis factor a (TNF-a), interleukin 6 (IL-6), NF-kB, ACC,
ChREBP, PPAR-g, carnitine palmitoyltransferase 1 (CPT-1), SREBP-1 c, and SIRT1
mRNA were determined by quantitative real-time reverse transcriptase PCR
(qRT-PCR) using SYBR Green reagent (Applied Biosystems, Grand Island, NY,
USA) in a PlusOne platform (Applied Biosystems).
Hematoxylin and eosin staining
Liver samples were ﬁxed in formaldehyde solution (10%) and embedded in
parafﬁn serially sectioned at 5 mm, stained with hematoxylin and eosin (HE), and
evaluated under a conventional light microscope using an Olympus BX50 mi-
croscope (Tokyo, Japan). Images of fat tissue areas (10 ocular and 40 objective
lenses) were captured with Evolution LC color light camera (Media Cybernetics,
Rockville, MD, USA).
Statistical analysis
All data were transferred to GraphPad Prism software (Version 5.0, GraphPad
Software Inc., San Diego, CA, USA) and analyzed with conﬁdence 95% (P < 0.05).
Data are expressed as the mean SD. The statistical signiﬁcance of differences in
mean values among mice groups was assessed by one-way ANOVA followed by
Bonferroni post-test.
Results
Mice treated with resveratrol did not reduce their food intake
(ST: 0.13  0.024; HFD: 0.13  0.024; HFD þ RSV: 0.12  0.016;
P ¼ 0.646), but signiﬁcant decrease was observed in ﬁnal bodyweight in the ST group (ST: 23.34  1.56; HFD: 25.69  2.17; HFD
þ RSV: 24.36  2.56; P ¼ 0.031) and in fat pad weight in the HFD
þ RSV group (ST: 0.026  0.013; HFD: 0.037 0.012; HFDþ RSV:
0.019  0.008; P ¼ 0.027) in relation to the HFD group.
The HFD þ RSV group had reduced concentrations of total
cholesterol (ST: 112.6  30.14; HFD: 181.2  37.14; HFD þ RSV:
117.8  19.92) and triacylglycerols (ST: 173.4  16.47; 200.2 
46.12; 126.6  39.47) (Fig. 1A, B). In the HFD group, HDL
cholesterol was signiﬁcantly decreased (ST: 18.59  2.67; HFD:
14.33  2.21; HFD þ RSV: 27.04  8.88) (Fig. 1C). Regarding pa-
rameters related to liver damage, values of ALT (ST: 35.18 11.24;
HFD: 55.36  13.94; HFD þ RSV: 35.31  8.05) and AST (ST: 30.5
 7.04; HFD: 53.0  5.71; HFD þ RSV: 33.7  5.73) were signif-
icantly reduced in the HFD þ RSV group (Fig. 1D, E).
In addition, analysis indicated that the HFDþ RSV group had a
substantial decrease in the total liver weight in relation to HFD
mice. The liver histologic examinations in mice fed the HFD
indicated prominent steatosis (Fig. 1F). Hence, we performed a
histologic analysis to examine the effect of resveratrol on the
development of fatty liver. Large hepatic lipid droplets were
diffusely present in the livers of the HFD group mice compared
with the other groups (Fig. 1F).
Analyses of mRNA expression of adipogenesis-related genes
indicated that ACC (ST: 0.84 0.18; HFD: 1.06 0.09; HFDþ RSV:
0.72  0.09), PPAR-g (ST: 1.16  0.31; HFD: 1.32  0.10; HFD þ
RSV: 1.00  0.20), and SREBP-1 c (ST: 1.12  0.03; HFD: 1.20 
0.09; HFD þ RSV: 0.90  0.05) mRNA expression in the liver was
signiﬁcantly suppressed in HFD þ RSV (Fig. 2A, C). However, no
difference was noted in the expression of ChREBP (P¼ 0.651) and
CPT-1 (P ¼ 0.866) among groups (Fig. 2D, E).
The mRNA expression of proinﬂammatory cytokines by qRT-
PCR in liver indicated a signiﬁcant decrease in IL-6 (ST: 0.79 
0.26; HFD: 1.05  0.39; HFD þ RSV: 0.40  0.17), TNF-a (ST: 1.06
 0.22; HFD: 1.29  0.21; HFD þ RSV: 0.80  0.21), and NF-kB
(ST: 0.98 0.36; HFD: 1.59 0.34; HFDþ RSV: 0.99 0.15) in the
HFD þ RSV group (Fig. 3A, C). IL-1 b expression did not differ
among the groups (P ¼ 0.273) (Fig. 3D).
Fig. 3. Analyses of mRNA expression of proinﬂammatory cytokines and SIRT1 by qRT-PCR in liver. (A) IL-6. (B) TNF-a. (C) NF-kB. (D) IL-1 b. (E) SIRT1. Control mice (ST; white
bars), high-fat diet (HFD; black bars), and high-fat diet plus resveratrol (HFD þ RSV; gray bars). *P < 0.05, yP < 0.01 among HFD versus ST and HFD þ RSV.
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1.06 0.14; HFD: 1.18 0.23; HFDþ RSV: 1.79 0.44) expression
in the HFD þ RSV group (Fig. 3E).
Discussion
Resveratrol has been described as having signiﬁcant effects
on lipid metabolism. Several studies have indicated that RSV
treatment increases lifespan and improves insulin sensitivity,
reduced insulin-like growth factor 1 (IGF-I) levels, increased AMP-
activated protein kinase (AMPK) and peroxisome proliferator-
activated receptor c coactivator 1 a (PGC-1 a) activity, increased
mitochondrial number, and improved motor function at a dosage
of 30 mg/kg/d [8,20,21].
In this context, several studies have demonstrated reduced
fat accumulation either in isolated adipocytes or in adipose tis-
sue [21] and liver [24], increased fatty acid oxidation in skeletal
muscle [21], and reduced serum lipids induced by this poly-
phenol. All these effects support the hypothesis that resveratrol
could be a useful molecule for the prevention of obesity, stea-
tosis, and NAFLD.
Recent studies have demonstrated that resveratrol decreased
alcoholic fatty liver in mice by activating SIRT1 [25,26]. Wang
et al. suggested that resveratrol might attenuate fat deposition
by inhibiting SREBP-1 c expression via SIRT1-FOXO1 pathway
[25]. In addition, chemical activators of SIRT1 inhibit the SREBP
target gene expression in vitro and in vivo, correlating with
decreased hepatic lipid and cholesterol levels and attenuated
liver steatosis in diet-induced and genetically obese mice [26].
PPAR-g is a nuclear receptor central to glucose and lipid ho-
meostasis [27] and is upregulated in the liver of obese patients
with NAFLD, representing an additional reinforcing lipogenic
mechanism to SREBP-1 c induction in the development of he-
patic steatosis [28]. SIRT1 promotes fat mobilization in white
adipocytes by repressing PPAR-g.
Resveratrol has recently been described as a potent antiin-
ﬂammatory compound in different organs and cell types [29].
Regarding steatohepatitis, it has been reported that resveratrol
hampers the inﬂammatory response, suggesting that thisantiinﬂammatory effect could be responsible for the amelio-
rating effect in terms of hepatic lipid accumulation [24]. In
our study, hepatic steatosis was signiﬁcantly decreased in
mice treated with resveratrol. This effect was associated with a
decreased inﬂammatory markers production.
Several studies have reported that TNF-a, IL-6, and NF-kB are
increased in obesity, and this increase is correlated with
numerous metabolic disorders [30,31]. In patients with obesity,
adipose and liver tissues are characterized by high-intensity
inﬂammation and increased secretion of cytokines [32]. TNF-a,
IL-6, and NF-kB may be the most pernicious, because they alter
adipose tissue function, inﬂuence adipogenesis, and are involved
in the metabolic complications of obesity with NAFLD [33].
Recent works have demonstrated that the deletion of SIRT1 in
hepatocytes results in increased local inﬂammation [34]. Other
studies have reported that siRNA-mediated knockdown of SIRT1
in 3 T3-L1 adipocytes in vitro increases cytokine mRNA expres-
sion when cells are stimulated with TNF-a [35]. In vivo, over-
expression of SIRT1 reduces hepatic expression of TNF-a and IL-6
after chronic high-fat feeding [36].
The antioxidant and/or antiinﬂammatory effects of resvera-
trol have been demonstrated to play a role in either controlling
NF-kB activation or chromatin remodeling through modulation
of histone deacetylase (as sirtuins) activity and subsequently
inﬂammatory gene expression in lung epithelial cells [37]. Other
studies support the scenario inwhich immune responses and the
aging process can be enforced by the potentiation of NF-kB
transactivation efﬁciency. Longevity factors, such as SIRT1 and its
activators, might regulate the efﬁciency of the NF-kB signaling,
the major outcome of which is inﬂammatory aging via proin-
ﬂammatory responses [38].Conclusion
In conclusion, the present study indicates that oral treatment
with resveratrol offers a protective effect against the proin-
ﬂammatory response proﬁle in the liver and improves lipid
metabolism in high-fat–fed mice, decreasing liver lipogenesis
J. M. O. Andrade et al. / Nutrition 30 (2014) 915–919 919markers. These effects were associated with upregulation of
SIRT1.
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